Interruption of natalizumab therapy for multiple sclerosis: What are the risks?

Neurology

Volumn 76, Issue 22, 2011, Pages 1854-1855

  Naismith, Robert T ^a   Bourdette, Dennis ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATALIZUMAB; PLACEBO;

DISEASE ACTIVITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RECURRENCE RISK; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT WITHDRAWAL;

EID: 79958125165     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31821d7553     Document Type: Editorial

References (6)

1. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011;76:1858-1865.
2. Klawiter EC, Cross AH, Naismith RT. The present efficacy of multiple sclerosis therapeutics: is the new 66% just the old 33%? Neurology 2009;73:984-990.
3. Hartung HP. New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab. Lancet Neurol 2009;8:28-31.
4. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006;59:743-747. (Pubitemid 43673151)
5. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010; 68:295-303.
6. Tyler KL. Progressive multifocal leukoencephalopathy: can we reduce risk in patients receiving biological immunomodulatory therapies? Ann Neurol 2010;68:271-274.